06Jun
Supreme Court Decides Prescription Drug Preemption Case in Favor of Drug Manufacturer
The United States Supreme Court finally clarified its 11-year-old “clear evidence” standard for pharmaceutical preemption. In its much-anticipated opinion delivered by Justice Breyer, the Court unanimously reversed the Third Circuit’s holding that...
By:
Morrison & Foerster LLP - Class Dismissed
Related
Once typically excluded from the mergers and acquisitions (“M&A”) due diligence checklist, cyberse...
Read More >
On November 27, 2019, the Internal Revenue Service, U.S. Department of Labor, and U.S. Department of...
Read More >
In a decision published on November 22, 2019, the First Circuit reversed a district court’s prior d...
Read More >
Welcome to the 26th edition of our newsletter on developments in the automotive industry published b...
Read More >
Seyfarth Synopsis: In Toomey v. U of Arizona, No. 19-35 (D. Ar. June 24, 2019), the Magistrate Judg...
Read More >
On January 17, 2020, the Committee on Foreign Investment in the United States (“CFIUS”) published ...
Read More >